This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

3 Aug 2011

Daiichi Sankyo & Ranbaxy to Expand Business in Mexico with Olmesartan Medoxomil Launch

Daiichi Sankyo and Ranbaxy Laboratories have agreed to expand their business in Mexico with the launch of Olmesartan medoxomil.

Japan's Daiichi Sankyo Company and India's Ranbaxy Laboratories announced yesterday they have agreed to expand their business in Mexico with the launch of Olmesartan medoxomil. The product is expected to be introduced to the market before the end of 2011.


Olmesartan medoxomil is a member of the angiotensin receptor blocker (ARB) class of antihypertensive medications that help lower blood pressure by blocking the angiotensin II receptor on the blood vessels and antagonizing the release of the hormone which causes salt retention and increased blood volume.


Daiichi Sankyo Mexico S.A. de C.V (DSMX), a newly established subsidiary of Daiichi Sankyo, and Ranbaxy Mexico S.A de C.V. (RMEX) will leverage the Group’s Hybrid Business Model in Mexico by utilizing the business know-how

Related News